JP2019533695A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019533695A5 JP2019533695A5 JP2019522925A JP2019522925A JP2019533695A5 JP 2019533695 A5 JP2019533695 A5 JP 2019533695A5 JP 2019522925 A JP2019522925 A JP 2019522925A JP 2019522925 A JP2019522925 A JP 2019522925A JP 2019533695 A5 JP2019533695 A5 JP 2019533695A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- pharmaceutical composition
- composition according
- identified
- acute kidney
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 4
- 230000006378 damage Effects 0.000 claims 4
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 3
- 208000033626 Renal failure acute Diseases 0.000 claims 3
- 201000011040 acute kidney failure Diseases 0.000 claims 3
- 208000020832 chronic kidney disease Diseases 0.000 claims 3
- 208000033679 diabetic kidney disease Diseases 0.000 claims 3
- 230000003907 kidney function Effects 0.000 claims 3
- 102100029228 Insulin-like growth factor-binding protein 7 Human genes 0.000 claims 2
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 239000000090 biomarker Substances 0.000 claims 2
- 229940109239 creatinine Drugs 0.000 claims 2
- 230000024924 glomerular filtration Effects 0.000 claims 2
- 108010008598 insulin-like growth factor binding protein-related protein 1 Proteins 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 230000002485 urinary effect Effects 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 102000001554 Hemoglobins Human genes 0.000 claims 1
- 108010054147 Hemoglobins Proteins 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 102000019210 Metalloproteinase inhibitor 2 Human genes 0.000 claims 1
- 108050006602 Metalloproteinase inhibitor 2 Proteins 0.000 claims 1
- 102000036675 Myoglobin Human genes 0.000 claims 1
- 108010062374 Myoglobin Proteins 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 claims 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
- 229940126575 aminoglycoside Drugs 0.000 claims 1
- 238000007675 cardiac surgery Methods 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000002296 eclampsia Diseases 0.000 claims 1
- 229910001385 heavy metal Inorganic materials 0.000 claims 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 1
- 229960001101 ifosfamide Drugs 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 201000001474 proteinuria Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 210000005084 renal tissue Anatomy 0.000 claims 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims 1
- 229960001052 streptozocin Drugs 0.000 claims 1
- 229960001967 tacrolimus Drugs 0.000 claims 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000007631 vascular surgery Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662414479P | 2016-10-28 | 2016-10-28 | |
| US62/414,479 | 2016-10-28 | ||
| PCT/US2017/058787 WO2018081578A1 (en) | 2016-10-28 | 2017-10-27 | Use of antibodies to timp-2 for the improvement of renal function |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019533695A JP2019533695A (ja) | 2019-11-21 |
| JP2019533695A5 true JP2019533695A5 (https=) | 2021-02-25 |
| JP7100030B2 JP7100030B2 (ja) | 2022-07-12 |
Family
ID=62024058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019522925A Active JP7100030B2 (ja) | 2016-10-28 | 2017-10-27 | 腎機能の改善のためのｔｉｍｐ－２に対する抗体の使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20190263926A1 (https=) |
| EP (1) | EP3532101B1 (https=) |
| JP (1) | JP7100030B2 (https=) |
| CN (1) | CN110352073A (https=) |
| AU (1) | AU2017348365A1 (https=) |
| ES (1) | ES2908239T3 (https=) |
| WO (1) | WO2018081578A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ607703A (en) | 2008-10-21 | 2014-09-26 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| JP5763098B2 (ja) | 2009-12-20 | 2015-08-12 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
| NZ605698A (en) | 2010-06-23 | 2015-03-27 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| ES2734494T3 (es) | 2011-12-08 | 2019-12-10 | Astute Medical Inc | Métodos y usos para el diagnóstico de una lesión renal y de una insuficiencia renal |
| TR201807542T4 (tr) | 2013-01-17 | 2018-06-21 | Astute Medical Inc | Böbrek hasarı ve böbrek yetmezliği teşhisi ve prognozuna yönelik metotlar ve bileşimler. |
| US10300108B2 (en) | 2013-12-03 | 2019-05-28 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US11243202B2 (en) | 2015-04-09 | 2022-02-08 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| EP3465201A4 (en) | 2016-06-06 | 2020-08-26 | Astute Medical, Inc. | MANAGEMENT OF ACUTE KIDNEY DAMAGE USING INSULINOMIMETIC GROWTH FACTOR BINDING PROTEIN 7 AND TISSUE METALLOPROTEINASE 2 INHIBITOR |
| US11346846B2 (en) | 2017-02-06 | 2022-05-31 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US11718682B2 (en) | 2017-04-05 | 2023-08-08 | Astute Medical, Inc. | Assays for TIMP2 having improved performance in biological samples |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US459007A (en) | 1891-09-08 | Porte | ||
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| US6129914A (en) | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| DK1621554T4 (da) | 1992-08-21 | 2012-12-17 | Univ Bruxelles | Immunoglobuliner blottet for lette kæder |
| ES2162863T3 (es) | 1993-04-29 | 2002-01-16 | Unilever Nv | Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae. |
| US5532210A (en) | 1994-06-08 | 1996-07-02 | E. I. Du Pont De Nemours And Company | High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| GB9818110D0 (en) | 1998-08-19 | 1998-10-14 | Weston Medical Ltd | Needleless injectors and other devices |
| US6096002A (en) | 1998-11-18 | 2000-08-01 | Bioject, Inc. | NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method |
| HK1044159A1 (zh) | 1998-12-01 | 2002-10-11 | 蛋白质设计实验室股份有限公司 | 抗γ-干扰素的人化抗体 |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| NZ607703A (en) | 2008-10-21 | 2014-09-26 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| JP5763098B2 (ja) | 2009-12-20 | 2015-08-12 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
| RU2013107129A (ru) * | 2010-09-30 | 2014-11-10 | Нитто Денко Корпорейшн | Модуляция экспрессии timp1 и timp2 |
| TR201807542T4 (tr) * | 2013-01-17 | 2018-06-21 | Astute Medical Inc | Böbrek hasarı ve böbrek yetmezliği teşhisi ve prognozuna yönelik metotlar ve bileşimler. |
| EP3617234A1 (en) * | 2013-08-07 | 2020-03-04 | Astute Medical, Inc. | Assays for timp2 having improved performance in biological samples |
| US10300108B2 (en) * | 2013-12-03 | 2019-05-28 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
-
2017
- 2017-10-27 CN CN201780076765.5A patent/CN110352073A/zh active Pending
- 2017-10-27 JP JP2019522925A patent/JP7100030B2/ja active Active
- 2017-10-27 ES ES17865610T patent/ES2908239T3/es active Active
- 2017-10-27 AU AU2017348365A patent/AU2017348365A1/en not_active Abandoned
- 2017-10-27 WO PCT/US2017/058787 patent/WO2018081578A1/en not_active Ceased
- 2017-10-27 EP EP17865610.4A patent/EP3532101B1/en active Active
- 2017-10-27 US US16/345,375 patent/US20190263926A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019533695A5 (https=) | ||
| Cheruku et al. | Acute kidney injury after cardiac surgery: prediction, prevention and management | |
| Ronco et al. | Acute kidney injury | |
| Park et al. | High-dose versus conventional-dose continuous venovenous hemodiafiltration and patient and kidney survival and cytokine removal in sepsis-associated acute kidney injury: a randomized controlled trial | |
| Bagshaw et al. | Acute kidney injury in critical illness | |
| Ginès et al. | Hepatorenal syndrome | |
| Mariscalco et al. | Acute kidney injury: a relevant complication after cardiac surgery | |
| Brochard et al. | An official ATS/ERS/ESICM/SCCM/SRLF statement: prevention and management of acute renal failure in the ICU patient: an international consensus conference in intensive care medicine | |
| Parida et al. | Cardiac surgery-associated acute kidney injury | |
| Karvellas et al. | Acute kidney injury in cirrhosis | |
| JP2023002547A (ja) | 慢性腎疾患の治療のためのデュラグルチド | |
| Fiaccadori et al. | Ultrafiltration in heart failure | |
| Fadaii et al. | Prevalence of pulmonary hypertension in patients undergoing hemodialysis | |
| Sriperumbuduri et al. | New insights into mechanisms of acute kidney injury in heart disease | |
| Mazumder et al. | The diagnosis and non-pharmacological management of acute kidney injury in patients with cirrhosis | |
| Domi et al. | From pre-existing renal failure to perioperative renal protection: the anesthesiologist’s dilemmas | |
| Abdelwahed et al. | Effects of transjugular intrahepatic portosystemic shunt on renal and pulmonary function in hepatic decompensation with and without hepatorenal and hepatopulmonary syndromes: A review | |
| Pham et al. | Sickle cell disease | |
| Zhao et al. | Peritoneal dialysis effectively removes toxic substances and improves liver functions of liver failure patients. | |
| Green et al. | The heart in atherosclerotic renovascular disease | |
| N Kampaktsis et al. | Strategies to avoid TAVI-related acute kidney injury | |
| Guerrero-Domínguez et al. | Perioperative renal protection strategies in liver transplantation | |
| Tam et al. | Acute Kidney Injury and Renal Replacement Therapy: A Review and Update for the Perioperative Physician | |
| Disque et al. | The Patient with Severe Co-Morbidities: Renal Failure | |
| Bali et al. | Nephrotic syndrome and recurrent pulmonary oedema in bilateral atherosclerotic renal artery stenosis: resolution following renal angioplasty and stenting |